Exploring the links between cognitive processes and brain lesions through a verbal fluency task
The Links Between Executive and Linguistic Processes and Their Lesional Determinants From a Verbal Fluency Task
This study is testing how problems with thinking and speaking are connected to brain damage in people with cognitive diseases and stroke by using a verbal fluency test.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 302 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire, Amiens Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Amiens) |
| Trial ID | NCT05875103 on ClinicalTrials.gov |
What this trial studies
This study investigates how executive and linguistic processes relate to verbal fluency deficits in patients with cognitive neurodegenerative diseases and stroke. Participants will undergo a verbal fluency test, which is sensitive to brain diseases, to identify the origins of their deficits. By analyzing the results, researchers aim to clarify the lesion determinants associated with these cognitive challenges. The study utilizes advanced imaging techniques to better understand the brain structures involved in verbal fluency.
Who should consider this trial
Good fit: Ideal candidates include French-speaking patients aged 40 to 85 with cognitive neurodegenerative diseases or those who have suffered a stroke.
Not a fit: Patients with mental retardation, guardianship, or other brain conditions affecting cognition may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance diagnostic accuracy and treatment strategies for patients with cognitive impairments related to brain injuries.
How similar studies have performed: While the approach of linking cognitive processes to brain lesions is established, this specific study's methodology may provide novel insights into verbal fluency deficits.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * For Cognitive cortical neurodegenerative diseases PATIENTS * informed consentPatients between 40 and 85 years old, * French native language, * Social Security affiliation, * Can read, write and count (up to 36) and knows the alphabet * Assessed in Amiens University Memory Clinic for: * Mild severity impairment (MMSE\> 19) or major severity impairment related to: * AD according to Albert criteria and McKhann criteria * DCL according to McKeith criteria * FTLD according to Rascovsky criteria * CBD according to Armstrong's criteria * PSP according to Höglinger criteria * For Stroke PATIENTS * informed consent * Patients between 40 and 85 years old, * French native language, * Social Security affiliation, * Can read, write and count (up to 36) and knows the alphabet * Having suffered a stroke, hospitalized in neurology, visualized by imaging Exclusion Criteria: * Mental retardation or guardianship * Other current or past brain condition affecting cognition, including: * Severe head trauma * Epilepsy prior to stroke still requiring previous treatment * Parkinson disease, multiple sclerosis * Brain tumor or brain radiation therapy * Current or past schizophrenia or psychosis * Active or past psychiatric impairments requiring a stay\> 2 days in a specialized environment * Contra indication to MRI * Comorbidity with life expectancy \<1 year * Comorbidity affecting cognition in particular: * Alcohol (\> 3 glasses / day) or history of alcohol withdrawal syndrome * Opiate or cocaine addiction or opiate withdrawal syndrome * Renal failure (dialysis or creatinine clearance \<30) * Hepatic failure (spontaneous INR\> 1.5 or PT \<60%) * Respiratory failure requiring oxygen therapy * Heart failure (orthopnea\> 2 pillows) * Persistent vigilance disorder (NIHSS1a score ≤1) * Cancer with paraneoplastic syndrome * Treatment with gold salts, D Penicillamine or other treatment with cognitive effect * Patient under guardianship or curators or private under public law * Pregnant and / or lactating woman
Where this trial is running
Amiens
- CHU Amiens — Amiens, France (Recruiting)
Study contacts
- Study coordinator: Martine ROUSSEL, PhD
- Email: roussel.martine@chu-amiens.fr
- Phone: 0322668240
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.